(NASDAQ: NCNA) Nucana's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.52%.
Nucana's earnings in 2025 is -$42,906,756.On average, 6 Wall Street analysts forecast NCNA's earnings for 2025 to be -$1,130,070,715, with the lowest NCNA earnings forecast at -$1,935,510,448, and the highest NCNA earnings forecast at -$252,862,134. On average, 6 Wall Street analysts forecast NCNA's earnings for 2026 to be -$185,119,268, with the lowest NCNA earnings forecast at -$177,857,306, and the highest NCNA earnings forecast at -$190,558,144.
In 2027, NCNA is forecast to generate -$394,956,555 in earnings, with the lowest earnings forecast at -$627,096,270 and the highest earnings forecast at -$141,258,839.